GSK Statistics
Total Valuation
GSK has a market cap or net worth of $99.63 billion. The enterprise value is $127.02 billion.
| Market Cap | 99.63B |
| Enterprise Value | 127.02B |
Important Dates
The last earnings date was Wednesday, October 28, 2026, before market open.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | Nov 13, 2026 |
Share Statistics
GSK has 4.01 billion shares outstanding. The number of shares has decreased by -1.37% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.01B |
| Shares Change (YoY) | -1.37% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 84.54% |
| Float | 3.89B |
Valuation Ratios
The trailing PE ratio is 17.32 and the forward PE ratio is 9.94.
| PE Ratio | 17.32 |
| Forward PE | 9.94 |
| PS Ratio | 2.24 |
| Forward PS | 2.13 |
| PB Ratio | 4.09 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.02 |
| P/OCF Ratio | 8.34 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.64, with an EV/FCF ratio of 12.77.
| EV / Earnings | 21.99 |
| EV / Sales | 2.85 |
| EV / EBITDA | 8.64 |
| EV / EBIT | 9.73 |
| EV / FCF | 12.77 |
Financial Position
The company has a current ratio of 0.86, with a Debt / Equity ratio of 1.30.
| Current Ratio | 0.86 |
| Quick Ratio | 0.55 |
| Debt / Equity | 1.30 |
| Debt / EBITDA | 2.11 |
| Debt / FCF | 3.18 |
| Interest Coverage | 14.94 |
Financial Efficiency
Return on equity (ROE) is 28.27% and return on invested capital (ROIC) is 24.61%.
| Return on Equity (ROE) | 28.27% |
| Return on Assets (ROA) | 9.24% |
| Return on Invested Capital (ROIC) | 24.61% |
| Return on Capital Employed (ROCE) | 19.28% |
| Weighted Average Cost of Capital (WACC) | 4.99% |
| Revenue Per Employee | $666,241 |
| Profits Per Employee | $86,421 |
| Employee Count | 66,841 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 1.42 |
Taxes
In the past 12 months, GSK has paid $744.79 million in taxes.
| Income Tax | 744.79M |
| Effective Tax Rate | 10.42% |
Stock Price Statistics
The stock price has increased by +7.79% in the last 52 weeks. The beta is 0.28, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +7.79% |
| 50-Day Moving Average | 49.43 |
| 200-Day Moving Average | 52.34 |
| Relative Strength Index (RSI) | 51.23 |
| Average Volume (20 Days) | 5,817,916 |
Short Selling Information
The latest short interest is 14.58 million, so 0.73% of the outstanding shares have been sold short.
| Short Interest | 14.58M |
| Short Previous Month | 14.65M |
| Short % of Shares Out | 0.73% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.86 |
Income Statement
In the last 12 months, GSK had revenue of $44.53 billion and earned $5.78 billion in profits. Earnings per share was $2.86.
| Revenue | 44.53B |
| Gross Profit | 32.86B |
| Operating Income | 13.05B |
| Pretax Income | 7.15B |
| Net Income | 5.78B |
| EBITDA | 14.71B |
| EBIT | 13.05B |
| Earnings Per Share (EPS) | $2.86 |
Balance Sheet
The company has $3.93 billion in cash and $31.60 billion in debt, with a net cash position of -$27.67 billion or -$6.90 per share.
| Cash & Cash Equivalents | 3.93B |
| Total Debt | 31.60B |
| Net Cash | -27.67B |
| Net Cash Per Share | -$6.90 |
| Equity (Book Value) | 24.38B |
| Book Value Per Share | 6.21 |
| Working Capital | -3.75B |
Cash Flow
In the last 12 months, operating cash flow was $11.95 billion and capital expenditures -$2.00 billion, giving a free cash flow of $9.94 billion.
| Operating Cash Flow | 11.95B |
| Capital Expenditures | -2.00B |
| Depreciation & Amortization | 1.67B |
| Net Borrowing | 8.43B |
| Free Cash Flow | 9.94B |
| FCF Per Share | $2.48 |
Margins
Gross margin is 73.79%, with operating and profit margins of 29.31% and 12.97%.
| Gross Margin | 73.79% |
| Operating Margin | 29.31% |
| Pretax Margin | 16.05% |
| Profit Margin | 12.97% |
| EBITDA Margin | 33.02% |
| EBIT Margin | 29.31% |
| FCF Margin | 22.13% |
Dividends & Yields
This stock pays an annual dividend of $1.80, which amounts to a dividend yield of 3.65%.
| Dividend Per Share | $1.80 |
| Dividend Yield | 3.65% |
| Dividend Growth (YoY) | 7.71% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 63.14% |
| FCF Payout Ratio | 72.76% |
| Buyback Yield | 1.37% |
| Shareholder Yield | 5.01% |
| Earnings Yield | 5.77% |
| FCF Yield | 9.98% |
Analyst Forecast
The average price target for GSK is $59.12, which is 19.41% higher than the current price. The consensus rating is "Hold".
| Price Target | $59.12 |
| Price Target Difference | 19.41% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 3.76% |
| EPS Growth Forecast (3Y) | 4.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 1:1.25.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:1.25 |
Scores
GSK has an Altman Z-Score of 1.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.98 |
| Piotroski F-Score | 6 |